Bhumsuk Keam

Research interests

Publications

• Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2309719

• Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2021.12.014

• Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.04.001

• Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy232

• Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

  British Journal of Cancer · 2018 · https://doi.org/10.1038/s41416-018-0131-9

• Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.73.6785

• Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2016.71.9096

• Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

  Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw559

• Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1510016

• Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt127

• Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis

  Breast Cancer Research · 2011 · https://doi.org/10.1186/bcr2834

• Aggressiveness of Cancer-Care near the End-of-Life in Korea

  Japanese Journal of Clinical Oncology · 2008 · https://doi.org/10.1093/jjco/hyn031

• Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

  BMC Cancer · 2007 · https://doi.org/10.1186/1471-2407-7-203

Current projects

No projects listed.